Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...
Gespeichert in:
| Veröffentlicht in: | Cancer medicine (Malden, MA) MA), 2016-02, Vol.5 (2), p.169-181 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 169 |
| container_title | Cancer medicine (Malden, MA) |
| container_volume | 5 |
| creator | Li, Pengxiang Wong, Yu‐Ning Armstrong, Katrina Haas, Naomi Subedi, Prasun Davis‐Cerone, Margaret Doshi, Jalpa A. |
| description | Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC patients in a real‐world setting. Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group, for whom no significant treatment innovations happened during this period) across the pretargeted therapy era (2000–2005) and the targeted therapy era (2006–2010). RCC patients diagnosed in the targeted therapy era (N = 6439) showed improved survival compared to those diagnosed in the pretargeted therapy era (N = 7231, hazard ratio (HR) for all‐cause death: 0.86, P |
| doi_str_mv | 10.1002/cam4.574 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4735783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1762342114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4384-3ebb01988f424cd76617b4cffee0ea4a394ab14b2e0319643ed6255b5d6db10d3</originalsourceid><addsrcrecordid>eNp1kUuLFDEURoMozjAO-Ask4MZNjXncJFUbYWjGB4y4UNchlbrVnaZeJlU19L83zYxNK5jFTUIOh3vzEfKasxvOmHjvXQ83ysAzcikYqMJoCc_PzhfkOqU9y8swoQ1_SS6E1qAqoy7J_vsS17C6jrp-HLZ0cnPAYU70Icw76prVDR4bGnHIiMcuFxd9GMbe0TDQeYd0iji7uMU5cyvGtCR6uuf36KYDzTW9Ii9a1yW8ftqvyM-Pdz82n4v7b5--bG7vCw-yhEJiXTNelWULAnxjtOamBt-2iAwdOFmBqznUApnklQaJjRZK1arRTc1ZI6_Ih0fvtNQ9Nj6PE11npxh6Fw92dMH-_TKEnd2OqwUjlSllFrx7EsTx14Jptn1Ix9ndgOOSLDdaSBCcQ0bf_oPuxyXmv0pWiNKUlQJxJvRxTClie2qGM3vM0B4ztDnDjL45b_4E_kksA8Uj8BA6PPxXZDe3X-Eo_A2h-Kc5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2287895423</pqid></control><display><type>article</type><title>Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Pengxiang ; Wong, Yu‐Ning ; Armstrong, Katrina ; Haas, Naomi ; Subedi, Prasun ; Davis‐Cerone, Margaret ; Doshi, Jalpa A.</creator><creatorcontrib>Li, Pengxiang ; Wong, Yu‐Ning ; Armstrong, Katrina ; Haas, Naomi ; Subedi, Prasun ; Davis‐Cerone, Margaret ; Doshi, Jalpa A.</creatorcontrib><description>Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC patients in a real‐world setting. Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group, for whom no significant treatment innovations happened during this period) across the pretargeted therapy era (2000–2005) and the targeted therapy era (2006–2010). RCC patients diagnosed in the targeted therapy era (N = 6439) showed improved survival compared to those diagnosed in the pretargeted therapy era (N = 7231, hazard ratio (HR) for all‐cause death: 0.86, P < 0.01), while the change between the pre–post periods was not significant for advanced prostate cancer patients (HR: 0.97, P = 0.08). Advanced RCC patients had significantly larger improvements in overall survival compared to advanced prostate cancer patients (z = 4.31; P < 0.01). More detailed year‐to‐year analysis revealed greater survival improvements for RCC in the later years of the posttargeted period. Similar results were seen for cause‐specific survival. Subgroup analyses by nephrectomy status, age, and gender showed consistent findings. Patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Future studies should examine the real‐world survival improvements directly associated with targeted therapies.
Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group) across the pretargeted (2000–2005) and targeted (2006–2010) therapy eras. We found that patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Similar changes were not observed for advanced prostate cancer patients, for whom no significant treatment innovations happened during this period.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.574</identifier><identifier>PMID: 26645975</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Advanced renal cell carcinoma ; Aged ; Aged, 80 and over ; Angiogenesis ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer therapies ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - pathology ; Cell survival ; Clinical Cancer Research ; Clinical trials ; FDA approval ; Female ; Histology ; Humans ; Kaplan-Meier Estimate ; Kidney cancer ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Male ; Marital status ; Medical prognosis ; Metastasis ; metastatic kidney cancer ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Nephrectomy ; Original Research ; Patients ; Population Surveillance ; Population-based studies ; population‐based study ; Prostate cancer ; Renal cell carcinoma ; SEER Program ; Studies ; survival ; targeted therapies ; Treatment Outcome ; Trends ; Variables ; Young Adult</subject><ispartof>Cancer medicine (Malden, MA), 2016-02, Vol.5 (2), p.169-181</ispartof><rights>2015 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4384-3ebb01988f424cd76617b4cffee0ea4a394ab14b2e0319643ed6255b5d6db10d3</citedby><cites>FETCH-LOGICAL-c4384-3ebb01988f424cd76617b4cffee0ea4a394ab14b2e0319643ed6255b5d6db10d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735783/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735783/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26645975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Pengxiang</creatorcontrib><creatorcontrib>Wong, Yu‐Ning</creatorcontrib><creatorcontrib>Armstrong, Katrina</creatorcontrib><creatorcontrib>Haas, Naomi</creatorcontrib><creatorcontrib>Subedi, Prasun</creatorcontrib><creatorcontrib>Davis‐Cerone, Margaret</creatorcontrib><creatorcontrib>Doshi, Jalpa A.</creatorcontrib><title>Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC patients in a real‐world setting. Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group, for whom no significant treatment innovations happened during this period) across the pretargeted therapy era (2000–2005) and the targeted therapy era (2006–2010). RCC patients diagnosed in the targeted therapy era (N = 6439) showed improved survival compared to those diagnosed in the pretargeted therapy era (N = 7231, hazard ratio (HR) for all‐cause death: 0.86, P < 0.01), while the change between the pre–post periods was not significant for advanced prostate cancer patients (HR: 0.97, P = 0.08). Advanced RCC patients had significantly larger improvements in overall survival compared to advanced prostate cancer patients (z = 4.31; P < 0.01). More detailed year‐to‐year analysis revealed greater survival improvements for RCC in the later years of the posttargeted period. Similar results were seen for cause‐specific survival. Subgroup analyses by nephrectomy status, age, and gender showed consistent findings. Patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Future studies should examine the real‐world survival improvements directly associated with targeted therapies.
Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group) across the pretargeted (2000–2005) and targeted (2006–2010) therapy eras. We found that patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Similar changes were not observed for advanced prostate cancer patients, for whom no significant treatment innovations happened during this period.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Advanced renal cell carcinoma</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Cell survival</subject><subject>Clinical Cancer Research</subject><subject>Clinical trials</subject><subject>FDA approval</subject><subject>Female</subject><subject>Histology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Marital status</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>metastatic kidney cancer</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Nephrectomy</subject><subject>Original Research</subject><subject>Patients</subject><subject>Population Surveillance</subject><subject>Population-based studies</subject><subject>population‐based study</subject><subject>Prostate cancer</subject><subject>Renal cell carcinoma</subject><subject>SEER Program</subject><subject>Studies</subject><subject>survival</subject><subject>targeted therapies</subject><subject>Treatment Outcome</subject><subject>Trends</subject><subject>Variables</subject><subject>Young Adult</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUuLFDEURoMozjAO-Ask4MZNjXncJFUbYWjGB4y4UNchlbrVnaZeJlU19L83zYxNK5jFTUIOh3vzEfKasxvOmHjvXQ83ysAzcikYqMJoCc_PzhfkOqU9y8swoQ1_SS6E1qAqoy7J_vsS17C6jrp-HLZ0cnPAYU70Icw76prVDR4bGnHIiMcuFxd9GMbe0TDQeYd0iji7uMU5cyvGtCR6uuf36KYDzTW9Ii9a1yW8ftqvyM-Pdz82n4v7b5--bG7vCw-yhEJiXTNelWULAnxjtOamBt-2iAwdOFmBqznUApnklQaJjRZK1arRTc1ZI6_Ih0fvtNQ9Nj6PE11npxh6Fw92dMH-_TKEnd2OqwUjlSllFrx7EsTx14Jptn1Ix9ndgOOSLDdaSBCcQ0bf_oPuxyXmv0pWiNKUlQJxJvRxTClie2qGM3vM0B4ztDnDjL45b_4E_kksA8Uj8BA6PPxXZDe3X-Eo_A2h-Kc5</recordid><startdate>201602</startdate><enddate>201602</enddate><creator>Li, Pengxiang</creator><creator>Wong, Yu‐Ning</creator><creator>Armstrong, Katrina</creator><creator>Haas, Naomi</creator><creator>Subedi, Prasun</creator><creator>Davis‐Cerone, Margaret</creator><creator>Doshi, Jalpa A.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201602</creationdate><title>Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras</title><author>Li, Pengxiang ; Wong, Yu‐Ning ; Armstrong, Katrina ; Haas, Naomi ; Subedi, Prasun ; Davis‐Cerone, Margaret ; Doshi, Jalpa A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4384-3ebb01988f424cd76617b4cffee0ea4a394ab14b2e0319643ed6255b5d6db10d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Advanced renal cell carcinoma</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Cell survival</topic><topic>Clinical Cancer Research</topic><topic>Clinical trials</topic><topic>FDA approval</topic><topic>Female</topic><topic>Histology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Marital status</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>metastatic kidney cancer</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Nephrectomy</topic><topic>Original Research</topic><topic>Patients</topic><topic>Population Surveillance</topic><topic>Population-based studies</topic><topic>population‐based study</topic><topic>Prostate cancer</topic><topic>Renal cell carcinoma</topic><topic>SEER Program</topic><topic>Studies</topic><topic>survival</topic><topic>targeted therapies</topic><topic>Treatment Outcome</topic><topic>Trends</topic><topic>Variables</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Pengxiang</creatorcontrib><creatorcontrib>Wong, Yu‐Ning</creatorcontrib><creatorcontrib>Armstrong, Katrina</creatorcontrib><creatorcontrib>Haas, Naomi</creatorcontrib><creatorcontrib>Subedi, Prasun</creatorcontrib><creatorcontrib>Davis‐Cerone, Margaret</creatorcontrib><creatorcontrib>Doshi, Jalpa A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Pengxiang</au><au>Wong, Yu‐Ning</au><au>Armstrong, Katrina</au><au>Haas, Naomi</au><au>Subedi, Prasun</au><au>Davis‐Cerone, Margaret</au><au>Doshi, Jalpa A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2016-02</date><risdate>2016</risdate><volume>5</volume><issue>2</issue><spage>169</spage><epage>181</epage><pages>169-181</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC patients in a real‐world setting. Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group, for whom no significant treatment innovations happened during this period) across the pretargeted therapy era (2000–2005) and the targeted therapy era (2006–2010). RCC patients diagnosed in the targeted therapy era (N = 6439) showed improved survival compared to those diagnosed in the pretargeted therapy era (N = 7231, hazard ratio (HR) for all‐cause death: 0.86, P < 0.01), while the change between the pre–post periods was not significant for advanced prostate cancer patients (HR: 0.97, P = 0.08). Advanced RCC patients had significantly larger improvements in overall survival compared to advanced prostate cancer patients (z = 4.31; P < 0.01). More detailed year‐to‐year analysis revealed greater survival improvements for RCC in the later years of the posttargeted period. Similar results were seen for cause‐specific survival. Subgroup analyses by nephrectomy status, age, and gender showed consistent findings. Patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Future studies should examine the real‐world survival improvements directly associated with targeted therapies.
Utilizing the 2000–2010 SEER Research files, a pre–post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group) across the pretargeted (2000–2005) and targeted (2006–2010) therapy eras. We found that patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Similar changes were not observed for advanced prostate cancer patients, for whom no significant treatment innovations happened during this period.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>26645975</pmid><doi>10.1002/cam4.574</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer medicine (Malden, MA), 2016-02, Vol.5 (2), p.169-181 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4735783 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Advanced renal cell carcinoma Aged Aged, 80 and over Angiogenesis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Cell survival Clinical Cancer Research Clinical trials FDA approval Female Histology Humans Kaplan-Meier Estimate Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Male Marital status Medical prognosis Metastasis metastatic kidney cancer Middle Aged Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging Nephrectomy Original Research Patients Population Surveillance Population-based studies population‐based study Prostate cancer Renal cell carcinoma SEER Program Studies survival targeted therapies Treatment Outcome Trends Variables Young Adult |
| title | Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T21%3A41%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20among%20patients%20with%20advanced%20renal%20cell%20carcinoma%20in%20the%20pretargeted%20versus%20targeted%20therapy%20eras&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Li,%20Pengxiang&rft.date=2016-02&rft.volume=5&rft.issue=2&rft.spage=169&rft.epage=181&rft.pages=169-181&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.574&rft_dat=%3Cproquest_pubme%3E1762342114%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2287895423&rft_id=info:pmid/26645975&rfr_iscdi=true |